Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Position Cut by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale trimmed its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,580 shares of the company’s stock after selling 4,739 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Teva Pharmaceutical Industries were worth $1,277,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after acquiring an additional 1,031,400 shares during the period. Maple Rock Capital Partners Inc. grew its stake in shares of Teva Pharmaceutical Industries by 68.3% in the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after purchasing an additional 1,770,000 shares during the last quarter. Truist Financial Corp raised its holdings in shares of Teva Pharmaceutical Industries by 7.0% in the 2nd quarter. Truist Financial Corp now owns 3,885,251 shares of the company’s stock worth $63,135,000 after purchasing an additional 254,483 shares in the last quarter. Iron Triangle Partners LP lifted its stake in Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after purchasing an additional 1,469,864 shares during the last quarter. Finally, Tri Locum Partners LP grew its position in Teva Pharmaceutical Industries by 15.1% in the second quarter. Tri Locum Partners LP now owns 2,550,307 shares of the company’s stock worth $41,442,000 after buying an additional 334,119 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TEVA has been the subject of several research reports. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Barclays lifted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Up 0.1 %

TEVA stock opened at $18.45 on Friday. The company has a 50 day moving average of $18.02 and a two-hundred day moving average of $16.95. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a 12-month low of $8.55 and a 12-month high of $19.08. The company has a market cap of $20.90 billion, a price-to-earnings ratio of -47.31, a PEG ratio of 1.33 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.